On May 10, 2017 Varian Medical Systems (NYSE: VAR) reported it has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the ProBeam system for proton therapy in Japan (Press release, InfiMed, MAY 10, 2017, View Source [SID1234518988]). This approval is the latest example of the growing worldwide interest in proton therapy as an advanced treatment option for cancer patients. Varian will be showcasing the ProBeam system at the Particle Therapy Co-Operative Group (PTCOG), May 11-13, 2017 in Yokohama, Japan.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Varian’s ProBeam system is the first to offer fully-integrated intensity modulated proton therapy (IMPT) to enable more efficient adaptive proton therapy. Varian’s pencil beam scanning technology gives clinicians the ability to deliver the dose precisely in the tumor to minimize dose to healthy tissue. When combined with cone beam computed tomography (CBCT), the ProBeam system enables advanced image-guided adaptive therapy during the course of treatment helping to make it the most precise form of proton therapy available.

With proton therapy, the risk of damage to healthy tissues and potential side effects are reduced because proton beams can be controlled so that they deposit their energy within the tumor site rather than passing all the way through the patient. The treatment is particularly suitable for pediatric cancer cases as well as for adults.

"We are very pleased that the ProBeam system has now received Shonin approval," said Moataz Karmalawy, general manager of Varian’s Particle Therapy division. "This approval is an important step in the growing availability of proton therapy in Japan and around the world."

For more information on ProBeam, visit www.varian.com/proton